Board of directors

 

   

Göran Ando
Chairman of the Board of Directors

Dr. Ando was CEO of Celltech Group plc, UK, until 2004. He joined Celltech from Pharmacia, now Pfizer, where he was Executive Vice President and President of R&D with additional responsibilities for manufacturing, IT, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, Dr. Ando was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group, UK. He was also a member of the Glaxo Group Executive Committee. Dr. Ando serves as Chairman of Novo Nordisk A/S, and as board member of Novo A/S, Molecular Partners AG, and EUSA Pharma and ICMEC (International Centre for Missing and Exploited Children). He also serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd. Dr. Ando is a Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the U.S. Dr. Ando serves as Chairman of Symphogen's Remuneration Committee

   

Kirsten Drejer, M.Sc., Ph.D.
Co-founder and Executive Director
Kirsten Drejer has 30 years of experience in the pharmaceutical and biotech industry. Before joining Symphogen, Dr. Drejer held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her service on Symphogen's board of directors, Dr. Drejer is also a member of the board of directors of Vækstfonden (The Fund for Industrial Growth) and previously Danisco A/S until its acquisition by Dupont 2011 and The Danish National Advanced Technology Foundation.

 

   
Ron Eastman, MBA
Mr. Eastman, Managing Director of Essex Woodlands, has over 30 years of experience in building healthcare businesses. Mr. eastman began his career at American Cyanamid Company, where he spent 15 years managing pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, Mr. Eastman has helped build three private healthcare companies - Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company which grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer.  HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. At Rinat, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders.  Rinat was acquired by Pfizer for $500M in 2006. Mr. Eastman serves on the boards of Corium International, EluSys Therapeutics, Inc., IntegenX Inc., Open Monoclonal Technology, Inc. ("OMT"), Protein Simple and Revance Therapeutics, Inc. He holds a Bachelor of Arts from Williams College and a Master of Business Administration degree from Columbia University
 
   

Jeppe Christiansen, M.Sc. 
Mr. Christiansen holds a MSc. (Economy) from the University of Copenhagen. Since 2004 Mr. Christiansen has been CEO of Maj Invest A/S, of which he is also a co-founder. From 1986 to 1988, he worked as an economist in Sparekassen SDS. He came to LD Pensions in 1988 where he became Head of Fund Management and later Executive Vice President responsible for investments. From 1998 to 2004, Mr. Christiansen worked as Director in Danske Bank, responsible for international equity investments and corporate clients. Mr. Christiansen is a member of the board of directors of Novo A/S, Novo Nordisk A/S, Haldor Topsøe A/S and Kirkbi A/S.
 
 

 

John B. Landis, Ph.D.
Dr. Landis is an Adjunct Professor of Chemistry and holds his Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Kent State University. Dr. Landis joined the Bioanalytical Systems Inc. (BASi) Board of Directors in November 2009 and was elected Chairman of the Board on February 11, 2010. Dr. Landis previously served as Senior Vice President, Pharmaceutical Sciences of Schering-Plough Corporation, from 2003 until his retirement in 2008. Dr. Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies and devices. Dr. Landis is a current member of Purdue University's Chemistry Leadership Council and Dean's Leadership Council for the School of Science and serves on the Advisory Board of South West Michigan Life Science Venture Capital and NanoMed Scientific and on the board of directors of Metabolic Solutions Development Company.

 
   
     

Anthony Tolcher, MD FRCPC FACP
President and Co-Founder of START
Dr. Tolcher is a medical oncologist who has over 20 years experience in early drug development and clinical trials. He has been involved in many of the initial studies of new agents that subsequently were FDA approved for the treatment of cancer including trastuzumab emtansine(KadcylaTM), regorafenib (StivargaTM), liposomal vincristine (MarqiboTM), cabazitaxel (JevtanaTM), carfilzomib (KyprolisTM), gefitinib (IressaTM), erlotinib (TarcevaTM), and eribulin (HalavenTM). He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program.

 

   

Jeffrey H. Buchalter, MBA 

Jeffrey H. Buchalter has over thirty years' experience in the bio/pharmaceutical industry. His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organizations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas. Jeffrey has been recognized for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. He has also been a Collaborating Partner in the President's National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States. Jeffrey received Bachelor Degrees in both Science and Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University. 

 

 

   

Christoffer Søderberg, MSc in Finance and Accounting 

Christoffer Søderberg is Director, in Novo Large Investments leading investment processes and taking part in managing and developing the portfolio of investmentsPrior to joining Novo A/S, he was a Senior Principal at the Boston Consulting Group (BCG) leading the Copenhagen Private Equity and Principal Investors practice area. Prior to joining BCG, Mr. Søderberg worked at Falck A/S as Global Head of Group Strategy and M&A, and most recently as CFO Falck Assistance. Prior to joining Falck, he worked as a Director at Carnegie Investment Banking focusing on buy-and sell-side M&A. Christoffer Søderberg holds a BSc in International Business and an MSc in Finance and Accounting from the Copenhagen Business School.